New treatments and new choices for type 2 diabetes mellitus

Abstract

Get full access to this article

View all access options for this article.

References

Drucker

Nauck

MA.

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368:1696–705. doi:10.1016/S0140-6736(06)69705-5

Neumiller

Wood

Campbell

RK.

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010; 30:463–84. doi:10.1592/phco.30.5.463

Nissen

SE.

The rise and fall of rosiglitazone. Eur Heart J 2010; 31:773–6. doi:10.1093/eurheartj/ehq016